Typical Antipsychotics
Typical Antipsychotics - Related Videos
01:21
Antipsychotic Drugs: Typical and Atypical Agents
0 Views •
2024
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
07:35
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
0 Views •
Cited by 8 •
2014
Approaches for testing the effects of antipsychotic drugs (APDs) in Caenorhabditis elegans are demonstrated. Assays are described for testing drug effects on development and viability and on pharyngeal pumping rate. These methods are also applicable for pharmacogenetic experiments with drug classes other than APDs.
11:50
EEG Mu Rhythm in Typical and Atypical Development
0 Views •
Cited by 3 •
2014
Assessment of the EEG mu rhythm provides a unique methodology for examining brain activity and when combined with behaviorally based assays, can be a powerful tool for elucidating aspects of social cognition, such as imitation, in clinical populations.
01:30
Typical Model Studies
0 Views •
2025
Fluid mechanics model studies often utilize scaled-down systems to predict fluid behavior in full-scale environments, such as river flows, dam spillways, and structures interacting with open surfaces. Maintaining Froude number similarity in river models is crucial, as it replicates surface flow features like wave patterns and velocities. Practical constraints, however, can introduce geometric distortions, impacting how accurately these models represent the real system. Adjustments, such as...
01:28
Psychosis and Antipsychotic Drugs: Overview
0 Views •
2024
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
FAQs
Dopamine D2 receptor antagonism reduces excessive dopaminergic signaling associated with psychosis, but the same mechanism can affect circuits involved in movement and prolactin regulation. Consequently, symptom control and adverse effects are pharmacologically linked rather than separate phenomena. This relationship helps explain why a medication may lessen hallucinations or delusions while also producing motor effects or altered prolactin regulation.
Typical antipsychotics provide a useful reference point for understanding newer antipsychotic treatments. Their pharmacology centers on D2 receptor antagonism, showing how changing dopaminergic signaling can reduce psychotic symptoms while affecting other brain functions. This foundation helps students and clinicians interpret the balance between therapeutic benefit and adverse effects across antipsychotic therapy.
Extrapyramidal symptoms and tardive dyskinesia indicate motor-system concerns associated with treatment, while sedation, anticholinergic effects, and hyperprolactinemia represent other clinically important outcomes. Recognizing these categories helps connect receptor action with pharmacologic consequences. It also encourages assessment of treatment beyond symptom reduction, especially when evaluating tolerability and risks during psychiatric care.
In schizophrenia, typical antipsychotics are used to reduce psychotic manifestations such as hallucinations, delusions, and disorganized thinking. The relevant outcome is not simply whether medication is given, but whether these symptoms improve without unacceptable effects. Evaluating both dimensions gives treatment assessment a pharmacologic basis and keeps safety considerations central to psychiatric care.
Acute agitation is another setting in which these medications remain useful. In that context, the clinical objective is to address an agitated or psychotic presentation while maintaining attention to motor symptoms, sedation, anticholinergic effects, and prolactin-related problems. Their continued relevance therefore depends on balancing symptom-oriented treatment with recognition of medication-associated risks.
Monitoring should include extrapyramidal symptoms, tardive dyskinesia, sedation, anticholinergic effects, and hyperprolactinemia. These outcomes represent distinct safety domains linked to the drugs’ pharmacology, so assessment should look beyond changes in hallucinations, delusions, or disorganized thinking. This approach connects efficacy evaluation with tolerability and helps identify clinically important effects during psychiatric treatment.